Application of improved GalNAc conjugation in development of cost-effective siRNA therapies targeting cardiovascular diseases.
Li Q, Yin K, Ma HP, Liu HH, Li S, Luo X, Hu R, Zhang WW, Lv ZS, Niu XL, Gu MH, Li CL, Liu YS, Liu YJ, Li HB, Li N, Li C, Gu WW, Li JJ.
Li Q, et al. Among authors: liu hh, liu yj, liu ys.
Mol Ther. 2024 Mar 6;32(3):637-645. doi: 10.1016/j.ymthe.2024.01.008. Epub 2024 Jan 10.
Mol Ther. 2024.
PMID: 38204163